research use only
Cat.No.S9194
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other PAI-1 Inhibitors | Tiplaxtinin (PAI-039) Notoginsenoside R1 Loureirin B TM5275 Sodium TM5441 |
|
In vitro |
DMSO
: 61 mg/mL
(197.83 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 308.33 | Formula | C16H20O6 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 483-90-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C)(C(CC1=C(C=C2C(=C1OC)C=CC(=O)O2)OC)O)O | ||
| Targets/IC50/Ki |
PAI-1
37.31 μM
|
|---|---|
| In vitro |
Toddalolactone inhibits the binding between PAI-1 and uPA, and therefore prevented the formation of the PAI-1/uPA complex.
|
| In vivo |
Intraperitoneal injection of toddalolactone in mice significantly prolonged tail bleeding and reduced arterial thrombus weight in a FeCl3-induced thrombosis model. Moreover, the hydroxyproline level in the plasma and the degree of liver fibrosis in mice were decreased after intraperitoneal injection of toddalolactone in CCl4-induced mouse liver fibrosis model.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.